In another notable study, scientists tested combinatorial anti-CTLA-4 and anti-PD1/PD-L1 therapy in an animal model of metastatic OS, showing that this regimen resulted in the complete control of tumors and immunity to further tumor inoculation (166), suggesting that such therapy may be more beneficial than stand-alone monotherapy. This evidence concerns the gene PDCD1 and neoplasm.